Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

33.31 -0.60 (-1.77%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	912,636
Open	34.03
Bid (Size)	30.00 (500)
Ask (Size)	35.49 (1,500)
Prev. Close	33.91
Today's Range	33.30 - 34.33
52wk Range	25.16 - 36.48
Shares Outstanding	166,121,384
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alkermes to Report First Quarter Financial Results on May 5, 2026

April 21, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

April 16, 2026

From Alkermes plc

Via Business Wire

Performance

YTD	+17.9%	+17.9%
1 Month	+11.3%	+11.3%
3 Month	+0.6%	+0.6%
6 Month	+12.1%	+12.1%
1 Year	+19.6%	+19.6%

More News

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

April 14, 2026

From Alkermes plc

Via Business Wire

Alkermes PLC (NASDAQ:ALKS) Reports Strong Q4 Earnings Beat Amid Muted Market Reaction ↗

February 25, 2026

Via Chartmill

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge ↗

November 19, 2025

Via Stocktwits

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

Via MarketMinute

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

April 01, 2026

From Alkermes plc

Via Business Wire

The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals

March 31, 2026

Via Finterra

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

March 12, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

March 10, 2026

From Alkermes plc

Via Business Wire

Alkermes (ALKS) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

February 25, 2026

From Alkermes plc

Via Business Wire

Alkermes plc Announces CEO Succession Plan

February 25, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Alkermes plc

Via Business Wire

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Via The Motley Fool

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Via The Motley Fool

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

February 12, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

February 11, 2026

From Alkermes plc

Via Business Wire

Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

January 06, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 30, 2025

From Alkermes plc

Via Business Wire

Alkermes to Participate in Two Upcoming Investor Conferences

November 25, 2025

From Alkermes plc

Via Business Wire

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal ↗

November 14, 2025

Via Benzinga

Frequently Asked Questions

Is Alkermes plc - Ordinary Shares publicly traded?

Yes, Alkermes plc - Ordinary Shares is publicly traded.

What exchange does Alkermes plc - Ordinary Shares trade on?

Alkermes plc - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Alkermes plc - Ordinary Shares?

The ticker symbol for Alkermes plc - Ordinary Shares is ALKS on the Nasdaq Stock Market

What is the current price of Alkermes plc - Ordinary Shares?

The current price of Alkermes plc - Ordinary Shares is 33.31

When was Alkermes plc - Ordinary Shares last traded?

The last trade of Alkermes plc - Ordinary Shares was at 04/24/26 04:00 PM ET

What is the market capitalization of Alkermes plc - Ordinary Shares?

The market capitalization of Alkermes plc - Ordinary Shares is 5.53B

How many shares of Alkermes plc - Ordinary Shares are outstanding?

Alkermes plc - Ordinary Shares has 6B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.